Tuberculosis (TB) is the leading cause of adult death by a single infectious organism, accounting for over 2.3 million deaths per year worldwide. The emergence of drug resistance and the increased spread of TB promoted by the global epidemic of HIV are worsening the global tuberculosis problem. Clearly, novel strategies are needed to control the tuberculosis epidemic. The acquisition of basic knowledge of the causative agent of TB, Mycobacterium tuberculosis, is a prerequisite for developing such tools. The goal of this proposal has been to develop the set of tools necessary for the generation of mutants and the transfer of genes M. tuberculosis mutants. Using mycobacteriophages as a starting point, we have developed the first transformation systems for mycobacteria, the ability to generate random mutants with transposons, and, recently, the ability to efficiently generate targeted gene disruptions using specialized transduction. The combination of these tools with the acquisition of the genomic sequence of M. tuberculosis provides unprecedented opportunities to acquire basic knowledge of the tubercle bacillus. Indeed, our successes in developing these tools have allowed us to: i) determine the previously unknown targets of the anti-TB drugs isoniazid and ethionamide, ii) identify numerous novel genes required for M. tuberculosis virulence, and iii) to determine the genetic and functional basis for the attenuation of the TB vaccine strain, BCG. This proposal seeks to use these genetic systems in combinations with a number of newly developed screens for mutants defective in virulence traits. The tubercle bacillus has acquired the means to invade and multiply in macrophages. Moreover, M. tuberculosis has evolved mechanisms by which it overcomes effector mechanisms of the host's innate and adaptive immune responses. We plan to elucidate the mechanisms by which M. tuberculosis causes pathogenesis and overcomes the innate and adaptive immune responses of the host by screening for mutants that are defective in their abilities to: i) grow in mammalian lungs, ii) to modulate different cytokine responses, and iii) to grow and persist in immunocompetent and immunocompromised mice. Ultimately, the knowledge of mycobacterial virulence and persistence factors should lead to the development of novel drugs, vaccines, and immunotherapies to control tuberculosis. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Method to Extend Research in Time (MERIT) Award (R37)
Project #
2R37AI026170-16
Application #
6720651
Study Section
Special Emphasis Panel (ZRG1-BM-1 (04))
Program Officer
Sizemore, Christine F
Project Start
1988-12-01
Project End
2009-01-31
Budget Start
2004-02-01
Budget End
2005-01-31
Support Year
16
Fiscal Year
2004
Total Cost
$401,278
Indirect Cost
Name
Albert Einstein College of Medicine
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Vilchèze, Catherine; Copeland, Jacqueline; Keiser, Tracy L et al. (2018) Rational Design of Biosafety Level 2-Approved, Multidrug-Resistant Strains of Mycobacterium tuberculosis through Nutrient Auxotrophy. MBio 9:
Harbut, Michael B; Yang, Baiyuan; Liu, Renhe et al. (2018) Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity. Angew Chem Int Ed Engl 57:3478-3482
Vilchèze, Catherine; Weinrick, Brian; Leung, Lawrence W et al. (2018) Plasticity of Mycobacterium tuberculosis NADH dehydrogenases and their role in virulence. Proc Natl Acad Sci U S A 115:1599-1604
Vilchèze, Catherine; Kim, John; Jacobs Jr, William R (2018) Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice. Antimicrob Agents Chemother 62:
Bhatt, Kiranmai; Machado, Henrique; Osório, Nuno S et al. (2018) A Nonribosomal Peptide Synthase Gene Driving Virulence in Mycobacterium tuberculosis. mSphere 3:
Yang, Yong; Thomas, Joseph; Li, Yunlong et al. (2017) Defining a temporal order of genetic requirements for development of mycobacterial biofilms. Mol Microbiol 105:794-809
Qaqish, Arwa; Huang, Dan; Chen, Crystal Y et al. (2017) Adoptive Transfer of Phosphoantigen-Specific ?? T Cell Subset Attenuates Mycobacterium tuberculosis Infection in Nonhuman Primates. J Immunol 198:4753-4763
Stratton, Thomas P; Perryman, Alexander L; Vilchèze, Catherine et al. (2017) Addressing the Metabolic Stability of Antituberculars through Machine Learning. ACS Med Chem Lett 8:1099-1104
Ryan, Ali; Polycarpou, Elena; Lack, Nathan A et al. (2017) Investigation of the mycobacterial enzyme HsaD as a potential novel target for anti-tubercular agents using a fragment-based drug design approach. Br J Pharmacol 174:2209-2224
Hanauer, David I; Graham, Mark J; SEA-PHAGES et al. (2017) An inclusive Research Education Community (iREC): Impact of the SEA-PHAGES program on research outcomes and student learning. Proc Natl Acad Sci U S A 114:13531-13536

Showing the most recent 10 out of 89 publications